Thomas Gad founded Y-mAbs Therapeutics in April 2015 and has been a member of the Board of Directors since the Company’s inception. Mr. Gad serves as Founder, Vice Chairman of the Board of Directors, and Chief Business Officer. Inspired by his daughter’s transformational and challenging journey through years of high-risk neuroblastoma treatment and her experience receiving breakthrough immunotherapy at Memorial Sloan Kettering Cancer Center to overcome the cancer, Mr. Gad founded Y-mAbs Therapeutics, securing executive management and seed capital for the inception of the Company. Mr. Gad has more than 12 years of experience in the pharmaceutical industry, including business development, senior management, financing, and licensing negotiations. Mr. Gad has a Bachelor of Science degree in Business Administration from Pepperdine University, California, U.S.

Johan Wedell-Wedellsborg has been a member of our Board of Directors since September 2015. Mr. Wedell-Wedellsborg has been the owner and Chairman of the board of Weco A/S (“Weco”) since May 2001. Weco is involved in shipping, investments in biotechnology companies, real estate investments and the financial services industry. Mr. Wedell-Wedellsborg is the majority owner of WG Biotech ApS, one of our principal stockholders.Wedell-Wedellsborg is educated within shipping in Hamburg, Germany and has also worked out of London in the United Kingdom and Houston, Texas.

Ashutosh Tyagi, M.D. has been a member of our Board of Directors since November 2017, representing until the end of 2018 Scopia Capital Management LP, or Scopia Capital, an institutional alternative asset management firm. Dr. Tyagi was with Scopia Capital from 2010 to 2018 (as a partner from 2012 to 2018). At Scopia Capital, Dr. Tyagi managed global health care investments and was a Co-Portfolio Manager of Scopia Capital’s health care funds. Prior to joining Scopia, he worked at Lombard Odier, Morgan Stanley, and Citigroup. Dr. Tyagi received a B.A. in Asian Studies from the University of Michigan, an MBA from the University of Michigan Business School and an M.D. from the University of Michigan School of Medicine.

James I. Healy (Chairman) has served as a member of our Board of Directors since November 2017 and was appointed as Chairman of the Board of Directors on April 22, 2022. Dr. Healy has been a General Partner at Sofinnova Investments (formerly Sofinnova Ventures), a biotech investment firm, since June 2000. Prior to June 2000, Dr. Healy held various positions at Sanderling Ventures, Bayer Healthcare Pharmaceuticals (as successor to Miles Laboratories) and ISTA Pharmaceuticals, Inc. Dr. Healy is currently the Chairman of CinCor (CINC), a member of the board of directors for Atsena, Karuna (KRTX), Natera (NTRA) and the lead independent director of Bolt (BOLT) and a board observer at Visen. Previously, he served as a board member of Amarin Corporation, Auris Medical Holding AG, Edge Therapeutics, Inc., Hyperion Therapeutics, Inc., ObsEva SA, InterMune, Inc., Iterum Therapeutics plc, Anthera Pharmaceuticals, Inc., Coherus BioSciences, Inc., Durata Therapeutics, Inc., CoTherix, Inc., Movetis NV and several private companies. In 2011, Dr. Healy won the IBF Risk Innovator Award and was named as one of the industry’s top leading Life Science investors in 2013 by Forbes Magazine. Dr. Healy holds an M.D. and a Ph.D. in Immunology from Stanford University School of Medicine and holds a B.A. in Molecular Biology and a B.A. in Scandinavian Studies from the University of California, Berkeley. He was previously a Director on the National Venture Capital Association (NVCA) and the Board of the Biotechnology Industry Organization (BIO).

David N. Gill has been a member of our Board of Directors since December 2017. Mr. Gill has more than 30 years experience in medical device and life sciences industries. Mr. Gill served as Chief Financial Officer of Perspectum Ltd., a UK based diagnostic tools company from February 2021 to October 2021. Mr. Gill served as the President and Chief Financial Officer of EndoChoice, Inc., a medical device company focused on gastrointestinal disease, from April 2016 through the sale of the company in November 2016 and as Chief Financial Officer from August 2014 to November 2016. Previously, he served as the Chief Financial Officer of INC Research (now known as Syneos Health), a clinical research organization, from February 2011 to August 2013 after having served as a board member and its audit committee chairman from 2007 to 2010. Mr. Gill also currently serves on the board of Evolus, Inc. (EOLS). He previously served on the board of Strongbridge Biopharma plc. (SBBP), (acquired by Xeris Pharmaceuticals, Inc., in October 2021), Histogenics, Inc. (HSGX) (now Ocugen, Inc.), Melinta Therapeutics, Inc (MLNT)., and Strata Skin Sciences, Inc. (SSKN). Earlier in his career, Mr. Gill served in a variety of senior executive leadership roles for several medical device companies, including TransEnterix, NxStage Medical, CTI Molecular Imaging, Inc., Novoste Corporation and Dornier Medical. Mr. Gill holds a B.S. degree, cum laude, in accounting from Wake Forest University and an M.B.A. degree, with honors, from Emory University, and was formerly a certified public accountant.

Laura J. Hamill has been a member of our Board of Directors since June 2020. Ms. Hamill has extensive experience in the biopharmaceutical industry, with over 30 years of global commercial experience in a variety of executive leadership positions. Most recently Ms. Hamill served as Executive Vice President, Worldwide Commercial Operations, for Gilead Sciences, Inc., where she was accountable for 2,200 employees, $22 billion in annual revenue and led the commercial strategy and long-term planning. As a member of the executive team she contributed to the corporate strategy and governance. Ms. Hamill also held a number of U.S. and international executive roles at Amgen, Inc., over an 18-year career with her last role being Senior Vice President US Commercial Operations, managing 2,000 employees across all Amgen’s therapeutic areas with annual revenue of $20 billion. Ms. Hamill’s areas of therapeutic expertise include inflammation, oncology, gene therapy, nephrology, osteoporosis, cardiovascular disease, migraine, HIV, hepatology, GI and anti-infectives. Ms. Hamill currently serves on the board of directors of Pardes Biosciences, Inc. (Nasdaq: PRDS) BB Biotech AG, (a Swiss public listed company) and Scilex Holding Company (Nasdaq: SCLX). Ms. Hamill also is a board member for Unchained Labs, a private company. Ms. Hamill previously served on the board of Acceleron Pharma Inc., and AnaptysBio, Inc., (Nasdaq: ANAB). Ms. Hamill holds a B.A. in business administration from the University of Arizona.

Michael Rossi has been a member of the Company’s Board of Directors since November 2023. Mr. Rossi serves as President and Chief Executive Officer of Y-mAbs Therapeutics. He has more than 30 years of radiopharmaceutical, drug development, commercialization, and people leadership experience on a global scale, most recently as President, Medical Group at Mirion Technologies. Before Mirion, Mr. Rossi served as the Head of Radioligand Imaging for Advanced Accelerators Applications (AAA), a Novartis Company. He also spent five years at Jubilant Pharma, where he served in several different roles including, President of Jubilant Radiopharma, and brings experience from GE Healthcare, Tyco Healthcare/Mallinckrodt and Syncor International. Mr. Rossi earned a Bachelor of Science in Pharmacy from the University of the Sciences in Philadelphia and holds an Authorized Nuclear Pharmacist Certification from Butler University. He has served on several boards of directors and remains a Licensed Pharmacist in the state of Pennsylvania.

Mary Tagliaferri, M.D., has been a member of our Board of Directors since February 2024. Dr. Tagliaferri has 28 years of experience in pharmaceutical drug development in oncology, immunology and women’s health that includes extensive regulatory expertise. She is currently the Chief Medical Officer and Senior Vice President of Nektar Therapeutics, where she is responsible for numerous clinical studies evaluating novel therapeutics in oncology and establishing key strategic partnerships. Prior to joining Nektar in 2015, she served as Chief Medical Officer for KangLaiTe-USA, a privately held biotechnology company which develops oncology drug candidates in multiple solid tumor settings. Dr. Tagliaferri was also a Co-Founder, President and Chief Medical Officer of BioNovo, where she led the company’s clinical drug development strategy and global regulatory affairs, data management and biostatistics, and oversaw clinical operations and compliance. Dr. Tagliaferri currently serves on the board of Enzo Biochem, Inc. and she served on the board of RayzeBio, Inc. from 2021 until the company’s acquisition by Bristol-Myers Squibb in 2024. Dr. Tagliaferri earned her B.S. degree from Cornell University and her M.D. from the University of California, San Francisco (UCSF). Dr. Tagliaferri was honored as an Eminent Woman Leader in Healthcare by Inc. Magazine in 2023. She was named to the Women who Lead in Life Sciences and Most Influential Women in Business lists by the San Francisco Business Times in 2019. Dr. Tagliaferri was also recognized as Woman of the Year in 2012 by the State of California, Assembly District 14. She has been lead author or contributor to approximately 90 peer-reviewed journal publications.